DEUTSCHES HERZZENTRUM MUNCHEN

Their core work

The German Heart Centre Munich is a specialized cardiac hospital and research institution focused on cardiovascular diseases — from acute emergencies like cardiogenic shock to chronic conditions like atherosclerosis and atrial fibrillation. Their H2020 work spans clinical trials testing interventional cardiology devices (catheter ablation, ECMO support) and fundamental research into how psychological stress drives arterial disease through immune system pathways. They bring both bedside clinical expertise and bench-level immunology research to EU consortia, making them a bridge between basic cardiovascular science and patient-facing treatment innovation.

What they specialise in

How they've shifted over time

DHM's early H2020 work (2018) centred on acute cardiac emergencies — testing mechanical circulatory support (ECMO) for patients in cardiogenic shock after heart attacks. Their focus then broadened into the underlying disease mechanisms, with the ERC-funded STRATO project investigating how mental stress accelerates atherosclerosis via immune cell pathways. Most recently (2021), they moved into next-generation ablation technologies for atrial fibrillation, signalling a shift toward less invasive electrophysiology interventions using pulsed electric fields.

DHM is moving from emergency cardiac care toward understanding disease mechanisms and less invasive electrophysiology treatments, suggesting future interest in precision cardiology and immune-cardiovascular crosstalk.

How they like to work

DHM operates primarily as a clinical partner in multi-centre trials (EURO SHOCK, BEAT AF) while also capable of leading investigator-driven research, as shown by their ERC Starting Grant coordination on STRATO. With 27 unique partners across 12 countries from just 3 projects, they engage in broad European consortia rather than small focused teams. This pattern suggests a well-connected clinical centre that other groups seek out for cardiology expertise and patient access.

DHM has collaborated with 27 distinct partners across 12 countries through just 3 projects, indicating participation in large multi-centre clinical networks. Their reach is firmly pan-European, consistent with the multi-site clinical trial model common in cardiovascular research.

What sets them apart

DHM combines two capabilities rarely found together: a high-volume specialized cardiac hospital generating clinical trial data and an ERC-funded basic research programme on cardiovascular immunology. This dual clinical-mechanistic profile makes them particularly valuable for projects that need to connect laboratory findings to patient outcomes. For consortium builders, they offer direct access to cardiac patient cohorts in one of Germany's leading heart centres.

Highlights from their portfolio

• STRATO
  ERC Starting Grant (EUR 1.48M) where DHM is coordinator — investigates the under-explored link between mental stress, innate immunity, and atherosclerosis progression.
• BEAT AF
  Tests pulsed electric field ablation for atrial fibrillation, a technology that could displace current radiofrequency and cryotherapy approaches — high translational potential.